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Abstract
Background: African-Americans remain underrepresented in clinical research despite experiencing a higher burden
of disease compared to all other ethnic groups in the United States. The purpose of this article is to describe the
study design and discuss strategies used to recruit and retain African-American smokers in a pharmacokinetic
study.
Methods: The parent study was designed to evaluate the differences in the steady-state concentrations of
bupropion and its three principal metabolites between African-American menthol and non-menthol cigarette
smokers. Study participation consisted of four visits at a General Clinical Research Center (GCRC) over six weeks.
After meeting telephone eligibility requirements, phone-eligible participants underwent additional screening during
the first two GCRC visits. The last two visits (pharmacokinetic study phase) required repeated blood draws using an
intravenous catheter over the course of 12 hours.
Results: Five hundred and fifteen African-American smokers completed telephone screening; 187 were phone-
eligible and 92 were scheduled for the first GCRC visit. Of the 81 who attended the first visit, 48 individuals were
enrolled in the pharmacokinetic study, and a total of 40 individuals completed the study (83% retention rate).
Conclusions: Although recruitment of African-American smokers into a non-treatment, pharmacokinetic study
poses challenges, retention is feasible. The results provide valuable information for investigators embarking on non-
treatment laboratory-based studies among minority populations.
Background
Although African-Americans experience a disproportio-
nately high burden of disease [1,2], they remain under-
represented in clinical research [3-5,5-14]. Clinical
research studies traditionally have included predomi-
nantly White samples and only a small percentage of
minority participants. Therefore, findings of these stu-
dies have limited generalizability to African-Americans
or other racial/ethnic minority populations [5,9,15-18].
Reasons for low levels of participation of African-Ameri-
cans in research studies have included mistrust of the
medical and research communities, lack of awareness of
potential benefits of study programs, and barriers related
to low economic status [12,19]. While some investiga-
tors are beginning to address these barriers [20-25],
recruitment and retention of African-Americans in clini-
cal research studies remain a critical challenge [26].
Tobacco-related morbidity and mortality is higher
among African-Americans compared to other racial/eth-
nic groups in the United States [27]. However, African-
Americans remain underrepresented in smoking cessa-
tion and tobacco research [28]. While about 80% of
African-American smokers smoke menthol cigarettes
[29-31], smoking menthol cigarettes is associated with
decreased abstinence following bupropion treatment in
African-American smokers [32,33]. The purpose of the
parent study was to evaluate the differences in the
steady-state concentrations of bupropion and its three
principal metabolites between African-American
menthol and non-menthol cigarette smokers. Under-
standing the effect of menthol on bupropion metabolism
could inform the choice of smoking cessation medica-
tions to African-American smokers. This study is unique
and presents recruitment and retention challenges for
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any medium, provided the original work is properly cited.the following reasons: 1) unlike clinical trials, this study
was laboratory-based and involved a non-treatment-
seeking study population; 2) participants were neither
required to be interested in quitting nor motivated to
quit; 3) participants were not in need of clinical investi-
gation or treatment for any physical illness that would
motivate them to visit the hospital multiple times and
stay in the hospital for long hours of investigation. This
article describes the design, successful recruitment and
retention of African-Americans in our pharmacokinetic
study. We will discuss challenges and solutions regard-
ing recruitment and retention issues in the study, which
could provide useful information for investigators
embarking on similar research among minority
populations.
Methods
The study protocol was reviewed and approved by the
University of Kansas Medical Center Human Subjects
Committee. This study was conducted within the Gen-
eral Clinical Research Center (GCRC) at the University
of Kansas Medical Center.
Study Design
Figure 1 provides an overview of the study that included
screening and four visits to the GCRC. The study was
designed to provide information about possible interac-
tion between menthol in mentholated cigarettes and
bupropion (Zyban®, Glaxo SmithKline) by evaluating the
effects of menthol in mentholated cigarettes on the phar-
macokinetic (PK) profiles of bupropion and its three
principal metabolites: hydroxybupropion, threohydrobu-
propion, and erythrohydrobupropion. The study aimed
to recruit and enroll 20 African-American smokers of
mentholated cigarettes (menthol smokers) matched 1:1
with 20 African-American smokers of non-mentholated
cigarettes (non-menthol smokers) by gender, number of
cigarettes per day smoked (CPD), and body mass index
(BMI). Pharmacokinetic (PK) parameters of bupropion
and its three principal metabolites were assessed at
steady state under smoking and non-smoking conditions.
During the smoking condition which lasted 10-15 days,
subjects smoked their usual brand of cigarettes. This per-
iod was followed by a non-smoking condition lasting
another 10-15 days. The PK parameters were then
assessed between 1) menthol and non-menthol smokers,
and 2) smoking and non-smoking conditions.
Preparatory Phase
Recruitment
Participants were recruited using clinic-based and com-
munity-based strategies. Clinic-based strategies included
informing medical center staff about the study through
flyers, broadcast emails, departmental meetings, and
employee newsletters. Posters and flyers were distributed
at a community health center that serves a
predominantly African-American patient population.
Invitation letters were sent to former research partici-
pants who gave written consent to be contacted in the
future. Community strategies included paid advertise-
ments in neighborhood newspapers, the major city
paper, and on two radio stations with large African-
American audiences. Research staff provided flyers to
African-American business owners and religious organi-
zations. Those interested in the study were asked to call
the study office and speak with a study coordinator who
assessed their eligibility for the study.
Eligibility criteria
Eligible individuals identifi e dt h e m s e l v e sa sA f r i c a n -
American or Black, aged 18 years or older. They smoked
at least 10 cigarettes per day and had a BMI between 18
and 45 kg/m
2. Additionally, each participant must have
smoked either mentholated or non-mentholated cigar-
ettes exclusively for the past year. Consistent with con-
traindications for bupropion use, exclusion criteria
included predisposition to seizures, a diagnosis of buli-
mia or anorexia nervosa in the past year, an unstable
medical or psychiatric illness, alcohol dependency within
the last year, or a myocardial infarction in the last
month. In addition, individuals who planned to move
from the metropolitan area in the next month, or who
had used other forms of tobacco in the past 30 days, or
had used bupropion in the past 30 days were excluded
from participation, as were those currently using any
prescription or other medications contraindicated or
with known interaction with bupropion, those reporting
illicit drug use and women who were pregnant, breast-
feeding, or contemplating pregnancy in the next month.
Eligibility Screening
Eligibility screening was multi-staged: telephone eligibil-
ity screening was followed by medical screening, and
then, lastly, by screening for adverse events with medi-
cation and adherence to medication.
Telephone Screening
Study staff specifically informed callers that this was a
“non-treatment study to find out how the body breaks
down a medication called Zyban”. Research staff verified
individuals’ willingness to adhere to study instructions.
Interested individuals were screened on the phone
according to the eligibility criteria described above.
Those eligible were informed that medical screening
would include an additional medical history, a physical
examination and laboratory tests to rule out contraindi-
cations to bupropion use. They were instructed to fast
overnight prior to the medical screening visit. A written
copy of these instructions was mailed to all individuals
who had passed the telephone screening.
Medical Screening
Phone-eligible individuals came to the General Clinical
Research Center (GCRC) after an overnight fast. The
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pants during the informed consent process. Individuals
signed a written informed consent form. They provided
a 20 ml blood sample for a complete blood count, a
complete metabolic profile, and cotinine analysis.
Women also gave a urine sample for a pregnancy test.
The GCRC nurse took a medical history and examined
the participants. Participants completed a baseline
smoking history questionnaire and also completed a
smoking topography using a CreSSmicro smoking topo-
graphy device (Plowshare Technologies, Baltimore, MD).
The study staff and the study physician reviewed the
results of the laboratory tests, medical history and physi-
cal examination findings to determine eligibility. Eligible
participants were given a sterile container for collecting
urine beginning 24 hours prior to the next visit to verify
their menthol status. They were also given a special
cigarette carrying container (Smartpak) to use during
the study.
Reporting adverse events and verifying medication
adherence
Medically eligible participants were given a 7-10 day
supply of placebo in a container with a Medication
Event Monitoring System (MEMS) cap, an adherence
verification device (AARDEX, Union City, CA). On their
second visit, participants were asked about adverse
events using the Common Terminology Criteria for
Adverse Events, version 3.0 (National Cancer Institute).
Unused study medication was collected and counted,
and data were downloaded from the MEMS cap. Indivi-
duals who did not tolerate the placebo medication or
used less than 75% of the prescribed dose were excluded
from continued participation. Such individuals were
excluded with the rationale that they were unlikely to
take the active medication as prescribed during the
entire study. Participants were enrolled in the pharma-
cokinetics phase of the study after they passed the medi-
cal adherence eligibility screening (Visit 2), and were
scheduled for Visit 3. The participants continued to use
the MEMS cap for the entire study to monitor bupro-
pion use. The study staff instructed participants to bring
their MEMS cap and all medications to each GCRC
visit.
Pharmacokinetic Study Phase
Procedure overview
After a seven-day placebo run-in period and an initial
three-day dosing period of 150 mg/day, participants
were given 300 mg/day (150 mg 2×/day) sustained-
release bupropion for 20-25 days. Participants were
asked to smoke their usual brand of cigarettes ad lib for
the first 10-15 days (smoking condition) and to quit
smoking for the remaining 10-15 days of the study
(non-smoking condition). Blood samples were drawn for
pharmacokinetics (PK) analysis on two occasions, 10-15
days after the commencement of bupropion while parti-
cipants were still smoking (PK 1), and again at days 20-
25 (PK 2) when they were required not to smoke (non-
smoking condition). The blood samples at Visit 3 (PK 1)
provided PK parameters when participants were exposed
to both bupropion and menthol in cigarettes. Samples at
Visit 4 (PK 2) provided PK parameters when partici-
pants were exposed only to bupropion but not to
menthol. At each PK visit, approximately 10 ml of blood
specimens for PK were taken through an intravenous
line inserted into the participant’s arm prior to ingestion
o f1 5 0m gb u p r o p i o n - S Ra n da t1 ,2 ,2 . 5 ,3 ,3 . 5 ,4 ,5 ,6 ,
8, and 12 hours after ingestion of the first dose of 150
mg bupropion-SR. Use of the second dose of bupropion
for the day was delayed until after all blood draws were
completed.
Retention Strategies
Reminders
Once participants were scheduled for visits, reminder
letters were mailed one week before each visit, and
reminder telephone calls were placed two days and one
day before each visit. The study staff provided informa-
tion about the procedures that participants would
undergo in the upcoming visit and answered questions.
Participants who missed an appointment were contacted
by telephone to reschedule the appointment, provided
they were still within the study visit window. The
research team met weekly to review recruitment and
Figure 1 Overview of the study design to evaluate the effect of menthol on the pharmacokinetics of bupropion and its metabolites.
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staff.
Incentives
Monetary compensation was discussed with participants
during the informed consent process. Participants were
given $50 Visa gift cards for each screening visit and
$150 Visa gift cards for each pharmacokinetic study
visit. Fifty dollar Visa gift cards were given to the parti-
cipants for the use of Smartpak and MEMS devices.
Additional $50 Visa gift cards were given to participants
who were able to abstain from smoking during the non-
smoking phase (verified with Nic check).
Data Analysis
This is a descriptive summary and, as such, we summar-
ized categorical variables by frequencies and percentages
and continuous variables by means and standard devia-
tions using SAS statistical package, version 9.1.
Results
Recruitment was conducted from February 2006 to Feb-
ruary 2007, during which time a total of 515 African-
American smokers were screened via telephone. Inter-
ested individuals learned about the study from newspa-
pers (58.7%), word of mouth (14.6%), and flyers (8.5%)
See Figure 2. Similarly, newspaper advertisement pro-
duced the highest yield of participants enrolled in the
pharmacokinetic study. Of the 515 screened, 187 were
phone-eligible (Figure 3). Some of the reasons for inelig-
ibility during phone screening included: smoking fewer
than 10 cigarettes per day; not smoking menthol or
non-menthol cigarettes exclusively; smoking other
tobacco products such as “Black and Mild” cigars; exces-
sive drinking of alcohol; and inability to attend 12-hour
appointments.
In total, 92 smokers were scheduled for Visit 1, and 81
kept their appointments. Figure 3 presents an overview
of participant retention, which shows 40 participants
completing all study visits. Figure 4 provides a summary
of the primary reasons for exclusion. Of the 81 smokers
who attended Visit 1, 41 (50.6%) were excluded due to:
medication non-adherence (12.3%); failure to keep
appointments (12.3%); illicit drug use (9.9%); failure to
establish IV lines (8.7%); protocol violations (4.9%); or
abnormal test results (2.5%).
Table 1 presents the characteristics of the participants
who were enrolled in the pharmacokinetic study (n =
48). Participants were approximately 51 (SD = 9.7) years
old and smoked an average of 15.1 (SD = 4.6) cigarettes
per day for a mean duration of 33 years. Fifty-eight per-
cent were females. The average BMI was 29.9 (SD =
7.0), and the mean age of smoking initiation was 17.6
(SD = 4.4) years.
Discussion
This study demonstrated that African-American smo-
kers can be successfully recruited to participate in an
intensive GCRC-based non-treatment study. Given the
intensity of participation required for the study, includ-
ing 24-hour urine collection, the use of cigarette and
pill monitoring devices, the number and duration of
study visits, and multiple blood draws, achieving this
recruitment level was considered a success. This out-
come supports the feasibility of including African-Amer-
icans in laboratory-based research. Showing that
African-Americans will volunteer to enroll in this type
of research is important, given the persistent national
problem of underrepresentation of African-Americans in
clinical studies [10]. The recruitment goal of the study
was to have 40 African-Americans complete the phar-
macokinetic study. We screened 515 and identified 187
eligible African-American smokers. Of 81 individuals
s c h e d u l e df o rt h em e d i c a ls c r e e n i n g( V i s i t1 )a tt h e
GCRC, 49.4% completed the full PK study. It should be
noted that it took approximately 12 months to meet this
enrollment goal, a much longer time than is needed to
recruit the same number of smokers in most smoking
Figure 2 Sources of information about study. *The distribution represents 520 responses from 515 individuals screened on the phone.
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to the intensive nature of the protocol as well as the
location of the study. This study was located in an aca-
demic medical center and most of our participants
heard about the study through newspaper advertise-
ment. This is a departure from our previous study in a
community health center serving a predominantly low-
income African-American population. In that study,
word of mouth yielded more participants [37]. Our
advertisement strategies also played a role. Periodically,
we reviewed progress with recruitment methods and
invested more in newspaper advertisement, which
proved to be more effective compared to other sources.
Multiple factors contributed to recruitment success.
Our research team has a track record of successfully
engaging African-Americans in research studies, and we
applied this experience to our recruitment efforts
[32,34,37-53]. We emphasized cultural competence and
cultural sensitivity training within our research team.
We involved the African-American community and
health care providers through a Community Advisory
Board in the planning and execution of our projects
[34]. Our efforts in the community have progressively
built trust, which is critical given that lack of trust is a
major impediment to the participation of African-Amer-
icans in medical research studies [12]. We integrated
Figure 3 Flow chart showing the recruitment and retention of participants in the pharmacokinetics study.
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of our participants. In this study, we achieved a rela-
tively high retention rate of 83%. Of the 48 participants
who met final eligibility criteria and enrolled in the
pharmacokinetic study, 40 participants completed the
study. This rate is similar to the retention rates of 84%
we obtained in our previous clinical trials [52,54], but
lower than 90%, reported in a more intensive long-term
clinical trial involving African-Americans with renal
insufficiency [55]. This implies that retention might be
better in a treatment-seeking population than in a non-
treatment-seeking population.
The recruitment of African-American non-menthol
smokers into our study was particularly challenging.
Only about 20% of African-American smokers smoke
non-menthol cigarettes [29-32,56]. Because of the lower
prevalence of African-American non-menthol smokers,
we could not enroll eligible menthol smokers until we
found non-menthol smokers who could be matched
with menthol smokers. Consequently, we had a long
waiting list of menthol smokers who, although eligible
for the study, could not be enrolled due to lack of a
non-menthol match. This sampling technique is prone
to selection bias and may limit the generalization of our
study findings. This limitation speaks to methodological
challenges pertaining to research involving menthol and
non-menthol African-American smokers.
The majority of the participants who were excluded
from this study after the informed consent process
either did not adhere to medication regimen or did not
keep the scheduled appointment. We do not know if
failure to attend visit during the abstinence phase was
due to the fact that some of the smokers could not stop
smoking during this phase. While the exclusion criteria
were carefully chosen to remove individuals who seemed
unlikely to comply with our protocol, this study also
provided insight into issues that warrant further investi-
gation, such as adherence to medication among minority
populations, and factors that influence minority partici-
pants to not keep the study appointments. Illicit drug
use (primarily marijuana) accounted for 19.5% of those
who were excluded from study after consenting to parti-
cipate. Although use of illicit drugs was a clear exclusion
criterion, we administered this question in person
because of its sensitive nature and the need to get more
accurate information along with a certificate of confi-
dentiality on their behalf from the federal government
agency for their protection.
Conclusions
Our study demonstrates the feasibility of recruiting Afri-
can-American smokers to a pharmacokinetic study, and
identifies unique challenges to recruitment and reten-
tion. These challenges include intense eligibility criteria
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Figure 4 Primary reasons for excluding participants from study after attending medical screening visit (n = 41).
Table 1 Baseline characteristics of participants enrolled in the PK study (n = 48)
All Menthol (n = 29) Non-Menthol (n = 19) P value
Mean age (SD) 50.9 (9.7) 47.4 (9.3) 56.3 (7.9) <0.001
1
Gender, n (% female) 28 (58.3%) 16 (57.1%) 12 (42.9%) 0.77
2
BMI* 29.9 (7.0) 30.5 (7.0) 29.0 (7.1) 0.48
Mean age of smoking initiation 17.6 (4.4) 18.0 (5.1) 16.9 (3.1) 0.34
Mean age of regular smoking 19.7 (5.0) 19.9 (5.9) 20.9 (4.5) 0.70
No. of years smoked 33.4 (10.1) 29.4 (9.4) 39.4 (7.8) <0.001
Mean CPD at baseline 15.1 (4.6) 15.3 (5.2) 16.1 (3.7) 0.33
1
FTND Score** 4.8 (1.7) 4.5 (1.6) 5.2 (1.8) 0.18
1Wilcoxon rank sum test;
2Fisher’s exact test; all other p-values calculated with t -tests;
*Body Mass Index. **Fagerström Test of Nicotine Dependence.
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invasive procedures. Despite these, we have demon-
s t r a t e dt h a tr e c r u i t i n gA f r i c a n-Americans in non-treat-
ment studies involving multiple blood draws and follow-
up visits can be accomplished effectively. This paper
provides valuable information for investigators embark-
ing on non-treatment laboratory-based studies among
minority populations.
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